Nurix Therapeutics (NRIX) said Thursday the US Food and Drug Administration has granted Fast Track designation for NX-5948 to treat adults with relapsed or refractory Waldenstrom's macroglobulinemia after at least two lines of therapy.

Fast Track designation is intended to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the company said.

Waldenstrom's macroglobulinemia is a rare, slow growing type of non-Hodgkin's lymphoma in which normal bone marrow cells are replaced by malignant lymphocytic cells, the company said.